---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-060221"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:03:39.673936+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Milestone restarts PSVT NDA for etripamil; cash of $89.5M funds into 2026

## Summary
- NDA for etripamil in PSVT resubmitted after FDA Type A meeting; standard review expected, potential approval in H1 2025.
- Cash, equivalents and short-term investments of $89.5M as of March 31, 2024, expected to fund operations into 2026.
- No revenue in Q1 2024 vs $1.0M in Q1 2023; net loss of $10.4M improved from $15.0M a year ago.
- R&D expense fell to $3.6M from $10.3M due to completion of Phase 3 PSVT studies.
- March 2024 public offering of common shares and pre-funded warrants raised net proceeds of ~$32.2M for development and commercialization.

## SEC filing metadata
- accession: 0001104659-24-060221
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465924060221/0001104659-24-060221-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465924060221/tm2414191d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-060221
- JSON: https://secwatch.observer/filing/0001104659-24-060221.json
- Plain text: https://secwatch.observer/filing/0001104659-24-060221.txt

## Key facts
- Earnings Releases
  Milestone Pharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue no revenue, net income net loss was $10.4 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: no revenue
  - Net income: net loss was $10.4 million
  - Result: reported results
  source text: Milestone Pharmaceuticals Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1408443/000110465924060221/0001104659-24-060221-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.